Dive Brief:

潜水简介：

The gene editing company Metagenomi, which went public earlier this year, said a development partnership struck with Moderna in 2021 has ended after the two companies “mutually agreed” to part ways.

今年早些时候上市的基因编辑公司Metagenomi表示，在两家公司“共同同意”分道扬镳后，2021年与Moderna达成的发展合作关系已经结束。

As part of the original deal, Moderna gave Metagenomi an upfront cash payment and was set to pay fees and possible milestones it if chose to license a program that emerged from the collaboration. Moderna also made an investment in the company in 2021 and is still a shareholder, Metagenomi said Wednesday..

作为原始协议的一部分，Moderna向Metagenomi支付了预付现金，并准备支付费用和可能的里程碑，如果它选择许可合作产生的项目。梅塔吉诺米周三表示，摩德纳还在2021年对该公司进行了投资，目前仍是该公司的股东。。

Metagenomi has now regained full rights to its gene editing technologies, including base editors and RNA-mediated integration systems, the company said. The companies also ended their collaboration studying a condition called primary hyperoxaluria type 1, or PH1.

该公司表示，Metagenomi现已恢复其基因编辑技术的全部权利，包括基础编辑和RNA介导的整合系统。两家公司还结束了合作，研究了一种称为原发性高草酸尿症1型（PH1）的疾病。

Dive Insight:

潜水洞察：

While Metagenomi executives said they were happy to regain rights to the technology involved in the Moderna collaboration, the company’s shares dropped nearly 20% in morning trading Thursday.

虽然Metagenomi高管表示，他们很高兴重新获得Moderna合作所涉及技术的使用权，但该公司股价在周四上午的交易中下跌了近20%。

Losing Moderna as a partner removes a potential source of incoming cash in the form of milestone payments as well as the expertise that the larger company offered in messenger RNA, Chardan analyst Geulah Livshits wrote in a note to investors. Still, it does give Metagenomi more flexibility with its pipeline and for recruiting potential future partners, she said..

Chardan分析师GeulahLivshits在给投资者的一份报告中写道，失去Moderna作为合作伙伴，意味着失去了里程碑式付款形式的潜在现金来源，以及这家较大公司在messenger RNA中提供的专业技能。她说，尽管如此，它确实为Metagenomi的渠道和招募潜在的未来合作伙伴提供了更多的灵活性。。

There were no data issues in the PH1 work that prompted the end of the collaboration, Metagenomi executives told investors and analysts on a conference call Wednesday. “We demonstrated very strong preclinical proof of concept,” Chief Medical Officer Sarah Noonberg said. Instead, the decision resulted from a “strategic prioritization” undertaken by Moderna, Metagenomi said..

Metagenomi高管周三在电话会议上告诉投资者和分析师，PH1工作中没有数据问题导致合作结束。首席医疗官莎拉·诺伯格（SarahNoonberg）说：“我们证明了非常有力的临床前概念证明。”。梅塔吉诺米说，相反，这一决定是由Moderna进行的“战略优先排序”产生的。。

In an email, a Moderna spokesperson said the company is still involved in gene editing research, pointing to the company’s other collaborations. Stat News reported Thursday that Eric Huang, previously head of Moderna’s genomics division, left the company earlier this year.

Moderna发言人在一封电子邮件中表示，该公司仍在参与基因编辑研究，并指出该公司的其他合作。《统计新闻》周四报道称，时任Moderna基因组部门主管的埃里克·黄（EricHuang）今年早些时候离开了该公司。

Metagenomi went public in February, raising almost $94 million in an initial offering by selling shares at $15 each. Its IPO was a rare instance of a preclinical biotech having success going public this year; most recent IPOs have been by more advanced drugmakers.

Metagenomi于2月份上市，通过以每股15美元的价格出售股票，在首次发行中筹集了近9400万美元。它的首次公开募股是临床前生物技术今年成功上市的罕见例子；最近的首次公开募股是由更先进的制药商进行的。

In the months since, the company’s shares have steadily dropped and are now worth about one-third of its offer price.

在此后的几个月里，该公司的股票稳步下跌，目前价值约为其发行价格的三分之一。

Metagenomi said it expects to report about $327 million in cash and cash equivalents as of the end of March when it finalizes its full financial results for the first quarter.

Metagenomi表示，预计截至3月底完成第一季度全部财务报表时，将报告约3.27亿美元的现金和现金等价物。